[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Xeris Biopharma Holdings insider Kevin McCulloch, listed as President and Chief Operating Officer, reported a transaction dated 10/02/2025. The filing shows 733 shares of common stock were disposed of at $8.31; the explanation states these shares were withheld by the issuer to satisfy tax and withholding obligations in connection with the net settlement of restricted stock units that vested on that date. After the reported transaction, Mr. McCulloch beneficially owns 1,700,426 shares directly. The report also lists 25,000 shares held indirectly by his spouse, with the reporting person disclaiming beneficial ownership except for pecuniary interest.

Positive

• Clear disclosure of transaction type and tax withholding on vested RSUs
• Direct beneficial ownership of 1,700,426 shares reported

Negative

• Shares were disposed (withheld) to satisfy taxes: 733 shares at $8.31

Insights

Corporate Governance Analyst

Insider net-settlement of vested RSUs reduced holdings by 733 shares on 10/02/2025.

The Form 4 records a net settlement withholding to cover taxes on vested restricted stock units, not an open-market sale; the filer lists 733 shares withheld at $8.31. Net-settlements are common when companies satisfy tax obligations without transferring cash from the insider.

The filing shows direct beneficial ownership of 1,700,426 shares and an indirect spouse-held block of 25,000 shares, with a disclaimer limiting claimed beneficial ownership to pecuniary interest. The transaction date is 10/02/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		F		733(1)	D	$8.31	1,700,426	D
Common Stock								25,000(2)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of October 2, 2025.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Kevin McCulloch report on Form 4 for XERS?

The Form 4 reports a net settlement where 733 shares were withheld to satisfy tax withholding for vested restricted stock units on 10/02/2025.

How many XERS shares does Kevin McCulloch beneficially own after the transaction?

The filing shows Mr. McCulloch directly beneficially owns 1,700,426 shares following the reported transaction.

Are there any indirect holdings disclosed for Mr. McCulloch in the XERS Form 4?

Yes. The report lists 25,000 shares held indirectly by his spouse; the reporting person disclaims beneficial ownership except for pecuniary interest.

What price is shown for the withheld shares in the Form 4?

The withheld shares are reported with a price of $8.31 per share.

What is the reporting person's role at Xeris Biopharma?

The Form 4 identifies the reporting person as President and Chief Operating Officer.